CTRV- CONTRAVIR PHARMACEUTICALS INC COM
ContraVir Pharma reports interim data for CMX157 from its ongoing Phase 2a multiple ascending dose clinical study; results consistent with earlier published clinical studies of Viread in HIV and HBV patients.
Not too late to get in.